title: Blocking cyclophilins in the chronic phase of asthma reduces the persistence of leukocytes and disease reactivation.
abstract: Allergic asthma is characterized by acute influxes of proinflammatory leukocytes in response to allergen stimulation, followed by quiescent (chronic) periods between allergen challenges, during which sustained, low-level inflammation is evident. These chronic phases of disease are thought to be mediated by populations of leukocytes persisting within airways and tissues. The lack of any in situ proliferation by these cells, along with their limited lifespan, suggests that a continual recruitment of leukocytes from the circulation is needed to maintain disease chronicity. The mechanisms regulating this persistent recruitment of leukocytes are unknown. Although classic leukocyte-attracting chemokines are highly elevated after acute allergen challenge, they return to baseline levels within 24 hours, and remain close to undetectable during the chronic phase. In the present study, we investigated whether an alternative family of chemoattractants, namely, extracellular cyclophilins, might instead play a role in regulating the recruitment and persistence of leukocytes during chronic asthma, because their production is known to be more sustained during inflammatory responses. Using a new murine model of chronic allergic asthma, elevated concentrations of extracellular cyclophilin A, but not classic chemokines, were indeed detected during the chronic phase of asthma. Furthermore, blocking the activity of cyclophilins during this phase reduced the number of persisting leukocytes by up to 80%. This reduction was also associated with a significant inhibition of acute disease reactivation upon subsequent allergen challenge. These findings suggest that blocking the function of cyclophilins during the chronic phase of asthma may provide a novel therapeutic strategy for regulating disease chronicity and severity.
authors.affiliation: Department of Microbiology, Immunology, and Tropical Medicine, George Washington University Medical Center, Washington, DC 20037, USA.
authors.forename: Erik J
authors.initials: EJ
authors.lastname: Stemmy
authors.forename: Molly A
authors.initials: MA
authors.lastname: Balsley
authors.forename: Rosalyn A
authors.initials: RA
authors.lastname: Jurjus
authors.forename: Jesse M
authors.initials: JM
authors.lastname: Damsker
authors.forename: Michael I
authors.initials: MI
authors.lastname: Bukrinsky
authors.forename: Stephanie L
authors.initials: SL
authors.lastname: Constant
mesh_terms: D000818:Animals; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000517:prevention & control; D021983:Cyclophilins / Q000037:antagonists & inhibitors* / Q000097:blood; D016572:Cyclosporine / Q000627:therapeutic use*; D005260:Female; D007962:Leukocytes / Q000187:drug effects*; D051379:Mice; D008807:Mice, Inbred BALB C; D055502:Secondary Prevention; D012720:Severity of Illness Index
chemical_list: D018927:Anti-Asthmatic Agents; D016572:Cyclosporine; C090438:(melle-4)cyclosporin; D021983:Cyclophilins